恩格列净对心力衰竭循环蛋白质组的影响:EMPEROR 项目机制洞察
本研究基于 EMPEROR-Reduced 和 EMPEROR-Preserved 中 1134 例患者,使用 Olink Explore 1536 平台检测基线、第 12 周和第 52 周的超过 1250 种循环蛋白,比较恩格列净与安慰剂。第 12 周时 1283 种蛋白中有 32 种达到差异表达阈值(变化≥10% 且错误发现率<1%),其中 9 种效应最大。差异蛋白常见生物学作用为促进心脏、肾脏或内皮自噬流,并与氧化应激降低、炎症和纤维化抑制、线粒体健康增强及肾脏钠重吸收调节相关。
要点
- 恩格列净治疗 12 周使 1283 种循环蛋白中 32 种差异表达(变化≥10%,FDR<1%)。
- 效应最大的 9 种蛋白包括 IGFBP1、转铁蛋白受体蛋白 1、碳酸酐酶 2、促红细胞生成素等。
- 差异蛋白常见作用为促进心脏、肾脏或内皮自噬流,并涉及抗氧化、抗炎、抗纤维化及调节钠重吸收。
核心结论
- 心力衰竭患者循环蛋白水平的变化与实验研究一致,提示 SGLT2 抑制剂的作用可能通过促进心脏和肾脏的自噬流、营养剥夺信号及跨膜钠转运来实现。
研究设计与样本
- 来自 EMPEROR-Reduced 和 EMPEROR-Preserved 的 1134 例患者,使用 Olink® Explore 1536 平台在基线、第 12 周和第 52 周检测超过 1250 种循环蛋白。
- 统计分析比较恩格列净与安慰剂,识别差异表达蛋白,并关联心脏和肾脏的已知生物学作用。
主要发现
- 第 12 周时,1283 种蛋白中有 32 种达到差异表达阈值(变化≥10%,错误发现率<1%)。
- 效应最大的 9 种蛋白为:胰岛素样生长因子结合蛋白 1、转铁蛋白受体蛋白 1、碳酸酐酶 2、促红细胞生成素、蛋白-谷氨酰胺 γ-谷氨酰转移酶 2、胸腺素 β-10、U 型线粒体肌酸激酶、胰岛素样生长因子结合蛋白 4、脂肪细胞脂肪酸结合蛋白 4。
- 基线至第 52 周的蛋白变化通常与基线至第 12 周的变化一致,但恩格列净在第 52 周使肾损伤分子-1 水平降低≥10%,而第 12 周无此变化。
- 差异表达蛋白最常见的生物学作用是促进心脏、肾脏或内皮的自噬流(6 种蛋白具有此特征)。
- 差异表达蛋白对心脏的其他作用包括降低氧化应激、抑制炎症和纤维化、增强线粒体健康与能量、修复和再生能力。
关键数值与推荐
- 差异表达阈值:蛋白水平变化≥10% 且错误发现率<1%(恩格列净 vs 安慰剂)。
- 第 12 周时 1283 种蛋白中 32 种达到差异表达阈值。
- 基线至第 52 周,恩格列净使肾损伤分子-1 水平降低≥10%,但第 12 周未达此阈值。
临床怎么用
- 恩格列净在心衰患者中的循环蛋白变化提示其机制涉及促进自噬流、调节营养剥夺信号和跨膜钠转运。
- 这些蛋白质组学发现支持 SGLT2 抑制剂对心脏和肾脏的多重保护作用,但尚不能直接用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse patient populations, but their mechanism of action requires further study. The aim is to explore the effect of empagliflozin on the circulating levels of intracellular proteins in patients with heart failure, using large-scale proteomics. METHODS AND RESULTS: Over 1250 circulating proteins were measured at baseline, Week 12, and Week 52 in 1134 patients from EMPEROR-Reduced and EMPEROR-Preserved, using the Olink® Explore 1536 platform. Statistical and bioinformatical analyses identified differentially expressed proteins (empagliflozin vs. placebo), which were then linked to demonstrated biological actions in the heart and kidneys. At Week 12, 32 of 1283 proteins fulfilled our threshold for being differentially expressed, i.e. their levels were changed by ≥10% with a false discovery rate <1% (empagliflozin vs. placebo). Among these, nine proteins demonstrated the largest treatment effect of empagliflozin: insulin-like growth factor-binding protein 1, transferrin receptor protein 1, carbonic anhydrase 2, erythropoietin, protein-glutamine gamma-glutamyltransferase 2, thymosin beta-10, U-type mitochondrial creatine kinase, insulin-like growth factor-binding protein 4, and adipocyte fatty acid-binding protein 4. The changes of the proteins from baseline to Week 52 were generally concordant with the changes from the baseline to Week 12, except empagliflozin reduced levels of kidney injury molecule-1 by ≥10% at Week 52, but not at Week 12. The most common biological action of differentially expressed proteins appeared to be the promotion of autophagic flux in the heart, kidney or endothelium, a feature of 6 proteins. Other effects of differentially expressed proteins on the heart included the reduction of oxidative stress, inhibition of inflammation and fibrosis, and the enhancement of mitochondrial health and energy, repair, and regenerative capacity. The actions of differentially expressed proteins in the kidney involved promotion of autophagy, integrity and regeneration, suppression of renal inflammation and fibrosis, and modulation of renal tubular sodium reabsorption. CONCLUSIONS: Changes in circulating protein levels in patients with heart failure are consistent with the findings of experimental studies that have shown that the effects of SGLT2 inhibitors are likely related to actions on the heart and kidney to promote autophagic flux, nutrient deprivation signalling and transmembrane sodium transport.
引用
- Zannad, Ferreira, Butler, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022. PMID: 36017745. doi:10.1093/eurheartj/ehac495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。